ReNeuron Group PLC

ReNeuron eyes profits after sustained efficacy in blindness treatment

ReNeuron Group PLC (LON:RENE) shares rose on Thursday after the group said its cell therapy for blindness-causing disease Retinitis Pigmentosa went well in the first group of phase II patients receiving the treatment. ReNeuron CEO Michael Hunt tells Proactive London the milestone announcement is significant but really only a taste of what's to come. News here too on ReNeuron's stroke efficacy treament and how the company intends to develop throughout 2019.
The RP announcememt comes after February’s update when the first three patients taking part in the phase I/II study were able to read an additional three lines of a standard eye chart.

Quick facts: ReNeuron Group PLC

Price: £2.05

Market: LSE
Market Cap: £65.26 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of ReNeuron Group PLC named herein, including the promotion by the Company of ReNeuron Group PLC in any Content on the Site, the Company receives...



Investor Update: Asiamet signs agreement with China Nonferrous Metals

Headlines from the Proactive UK newsroom. Asiamet (LON:ARS) has teamed up with China Nonferrous Metals to carry out an engineering evaluation on the BKM Copper project in Indonesia.  China NFC is currently building a zinc mine in Sumatra and is looking to expand its activities in the...

3 weeks, 5 days ago

2 min read